Physician profile
Rupal P Dumasia
NPI 1447278478
$5,469.68
in general payments reported to CMS, 2019-2025
12 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $834 · 2021: $73.74 · 2022: $421 · 2023: $493 · 2024: $39.17 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,676 · Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,676.08 |
| Food and Beverage | $1,144.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,929.13 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Evoque |
| Abbott Laboratories | $1,283.52 | 2025 | Triclip, Navitor |
| Medtronic Vascular, INC. | $805.90 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $743.34 | 2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Boston Scientific Corporation | $225.49 | 2019-2025 | Synergy, Watchman Flx |
| Akcea Therapeutics, INC. | $133.62 | 2019 | |
| Abiomed | $122.13 | 2019-2021 | |
| Cardiac Dimensions, INC. | $64.80 | 2024-2025 | |
| Ge Healthcare | $50.00 | 2023 | |
| Medtronic, INC. | $42.84 | 2024-2025 | Ffrangio, Corevalve Evolut R |
| Philips North America LLC | $42.62 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupal Dumasia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.